Supreem Pharmaceuticals Mysore Private Limited, a active private limited company, was established on 16 August 1996 in Nanjangudu, Karnataka, India. Engaging in preventive health supplements within the manufacturing sector, it holds CIN: U24231KA1996PTC020988. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹5.50 Cr and a paid-up capital of ₹3.94 Cr.
Formerly known as Candor Laboratories Limited, Candor Labs Private Limited.. It upholds a compliant status. Employing 207 professional, Its leadership includes Geetha Sadananda Nagaraja Rao (Whole-Time Director), Aditya Sadanand Rao (Whole-Time Director), Amit Sadanand Rao (Whole-Time Director). Past directors included Geetha Sadananda Nagaraja Rao, Sunil Mundra Laxminarayana, Venkatesh Tammiah Avadhany. It holds ₹47.34 Cr open charges and ₹6.70 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at # 73, 74 & 48P1, Kiadb Industrial Area,, Nanjangudu, Karnataka, 571302.
U24231KA1996PTC020988
020988
16 August 1996
₹5.50 Cr
₹3.94 Cr
Roc Bangalore
Unlisted
Active
Explore comprehensive insights into Supreem Pharmaceuticals Mysore Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Geetha Sadananda Nagaraja Rao | Whole-Time Director | 22 Jan 2008 | Current |
| Aditya Sadanand Rao | Whole-Time Director | 10 Jul 2020 | Current |
| Amit Sadanand Rao | Whole-Time Director | 10 Jul 2020 | Current |
| Sadanand Nagaraja Rao | Managing Director | 16 Aug 1996 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 10 Apr 2020 | Past |
| Pramod Abcsdd | Director | 31 Aug 2020 | Past |
| Pramod Abcsdd | Director | 15 Nov 2014 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Supreem Pharmaceuticals Mysore Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.32% increase. The company also saw a substantial fall in profitability, with a 617.53% decrease in profit. The company's net worth observed a substantial decline by a decrease of 46.82%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Supreem Pharmaceuticals Mysore had a promoter holding of 61.84% and a public holding of 38.16%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹473,425,000.00
₹67,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Jul 2023 | Axis Bank Limited | ₹9.04 Cr | Open |
| 09 Oct 2013 | Karnataka State Financial Corporation | ₹8.30 Cr | Open |
| 21 Nov 2007 | State Bank Of India | ₹29.65 Cr | Open |
| 20 Sep 2002 | State Bank Of India | ₹3.53 M | Open |
| 04 Mar 2015 | Karnataka State Financial Corporation | ₹2.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Supreem Pharmaceuticals Mysore has a workforce of 207 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Supreem Pharmaceuticals Mysore, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Supreem Pharmaceuticals Mysore's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Supreem Pharmaceuticals Mysore Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
Progress on Supreem Pharmaceuticals Mysore Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Bangalore. was documented.
A charge with Axis Bank Limited of Rs. 9.04 Cr registered on 11 Jul 2023 with Charge ID 100788923 was modified on 04 Sep 2023. was recorded as a recent event.
The activity A charge with Axis Bank Limited amounted to Rs. 9.04 Cr with Charge ID 100788923 was registered on 11 Jul 2023. was completed.
Progress on A charge with State Bank Of India of Rs. 29.65 Cr registered on 21 Nov 2007 with Charge ID 10081897 was modified on 04 Jan 2023. was documented.
Progress on Aditya Sadanand Rao was appointed as a Whole-time director was appointed as a Whole-time director on 10 Jul 2020 & has been associated with this company since 5 years 5 months . was documented.
The CIN of Supreem Pharmaceuticals Mysore Private Limited is U24231KA1996PTC020988.
Supreem Pharmaceuticals Mysore Private Limited is headquartered at # 73, 74 & 48P1, Kiadb Industrial Area,, Nanjangudu, Karnataka, 571302.
Supreem Pharmaceuticals Mysore Private Limited was incorporated on 16 August 1996.
The current directors of Supreem Pharmaceuticals Mysore Private Limited are
The primary industry of Supreem Pharmaceuticals Mysore Private Limited is Manufacturing.
Supreem Pharmaceuticals Mysore Private Limited is unlisted.
The authorized capital of Supreem Pharmaceuticals Mysore Private Limited is ₹5.50 Cr, and the paid-up capital is ₹3.94 Cr.
The compliance status of Supreem Pharmaceuticals Mysore Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX